• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Novartis

NYSE:NVS

$51.96 $0.23 (0.44%)

REAL-TIME: Last trade at

Is This Dow Heavyweight a Value Trap?

Pfizer: A $22 Stock Worth $25

Biogen Tysabri Canadian Label Update - Analyst Blog

Gen-Probe Remains Neutral - Analyst Blog

Healthcare Dogs Stay Steady In April

Pfizer: Don't Overlook This $22 Gem

Incyte Stays Neutral - Analyst Blog

Incyte Stays Neutral - Analyst Blog

Perrigo's Generic Portfolio Boosted - Analyst Blog

Guru Stocks at 52-Week Lows: NVS, BHP, SI, DCM, COP

Has Momenta Pharmaceuticals Become the Perfect Stock?

Pfizer Updates: Zithromax Associated With Heart Deaths; Xalcori Successful

RDY Adds to Generic Portfolio - Analyst Blog

Good News for Perrigo - Analyst Blog

FTS International To Form Saudi Arabia Joint Venture With Summit Technologies

Your Warning Label Is My Sales Brochure

How High Can Biogen Idec Fly?

Drug Fails: At Least It's Approved Already

Disappointing Data on Pfizer Drug - Analyst Blog

Has Ariad Pharmaceuticals Become the Perfect Stock?

Positive Data on Novartis' Lucentis - Analyst Blog

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

UPDATE: FDA Concludes Safety Review Of Novartis MS Drug Gilenya

FDA Approves Gen-Probe's PANTHER - Analyst Blog

Standard Review for Biogen's BG-12 - Analyst Blog

Investment Opportunities Popping Up in Europe

Food and drink, tobacco stocks weigh on Europe

GlaxoSmithKline: Complied With Indian Rules In Getting Heart, Lung Drug Approved

Has XOMA Become the Perfect Stock?

UPDATE: Drug Makers Refute India Allegations Of Regulatory Irregularities

Europe stocks inch higher in a choppy market

Novartis Scores in Phase III Study - Analyst Blog

Earnings Beat at PDL BioPharma - Analyst Blog

Novartis: Pasireotide Works Well In Acromegaly Trial

NHS Could Save GBP84.5 Million A Year If Avastin Used In Eye Disease-Study

UPDATE: FDA: Regeneron Drug Offers 'Small' Benefit In Gout

Best of the Blogs, Biotech: How Much Money Do the Top Pharma CEOs Make?

Novartis to Acquire Fougera - Analyst Blog

These Cold Stocks Are Heating Up

Novartis To Acquire Dermatology Generics Co Fougera For $1.53 Billion

See More Articles...